Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Long-term extension study of nemolizumab in prurigo nodularis
2024-514502-31-00Phase 3Completed
- Sponsor
- Galderma
- Start
- Jan 2021
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 16
01
Overview
Phase 3, open-label, single-arm trial of nemolizumab in prurigo nodularis (PN), sponsored by Galderma. Primary endpoints: Incidence and severity of adverse events and Re-entry subgroup primary endpoint. Started Jan 2021; status: completed.
02
Drugs
nemolizumab
03
Conditions
prurigo nodularis (PN)
Beyond the preview
Go deeper on 2024-514502-31-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2024-514502-31-00.